EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) has received an average recommendation of “Buy” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year […]